Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration approved Darzalex Faspro in combination with bortezomib, lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. “D-VRd is the only anti-CD38 antibody-based regimen with approved indications across newly diagnosed patients, regardless of transplant eligibility,” the company stated.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- FDA approves Darzalex Faspro combo for newly diagnosed multiple myeloma
- Johnson & Johnson call volume above normal and directionally bullish
- Johnson & Johnson Trending as Analysts Stick With Buy
- Top 3 Stocks to Watch Right Now, According to AI Analyst, 1/23/2026
- Johnson & Johnson Stock Trending Higher Among Analysts